SCHEMBL2293432

SCHEMBL2293432

O=C(CCl)ON1C(=O)C2C3C=CC(C3)C2C1=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 4/20 0.49
TDP1 Q9NUW8 1/20 0.49
RAB9A P51151 2/20 0.47
MAPK1 P28482 1/20 0.46
HTT P42858 3/20 0.46
LMNA P02545 1/20 0.46
PKM P14618 1/20 0.46
TSHR P16473 2/20 0.44
USP2 O75604 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
HPGD P15428 1/20 0.42
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4274070 0.87 MAPK1 (0.53) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL13764513 0.84 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL13599642 0.84 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL2293691 0.84 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL20099725 0.84 ALDH1A1 (0.49) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL13599603 0.84 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL11752804 0.84 MAPK1 (0.50) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL13599667 0.84 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL2584632 0.83 ALDH1A1 (0.55) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A
SCHEMBL4278263 0.83 RAB9A (0.50) SMN1; SMN2L3MBTL1ALDH1A1TDP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-20 US disclosed
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-13 US disclosed
US-7994315-B2 Intermediate compound for synthesizing pharmaceutical agent and production method thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
EP-2221305-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
EP-2221304-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 SMN1; SMN2 849/4885L3MBTL1 4453/4885ALDH1A1 1251/4885
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 SMN1; SMN2 849/4885L3MBTL1 4453/4885ALDH1A1 1251/4885
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 SMN1; SMN2 849/4885L3MBTL1 4453/4885ALDH1A1 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.